Get all premium features to the best stock analysis tool

IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Wells Fargo 21 st Annual Healthcare Conference Date: Wednesday, September 9, 2026 Format: 1x1 Meetings only Citi's 2026 Biopharma Back to School Conference Date: Thursday, September 10, 2026Time: 10:40 a.m.

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.